Background--Despite recent evidence demonstrating a potent protective effect of adoptively transferred regulatory T cells (Tregs) in ischemic stroke, the mechanism for Treg mobilization and activation in the ischemic brain is, remarkably, unknown. This study determines the role of C-C chemokine receptor type 5 (CCR5) in mediating the docking and activation of transferred Tregs in their protection of early blood-brain barrier disruption after stroke.
B
oth the innate and adaptive immune systems are rapidly activated in response to cerebral ischemia and reperfusion injury, 1,2 which leads to infiltration of various immune cells into the brain parenchyma. 3, 4 Accumulating evidence suggests the importance of these immune responses in the pathogenesis of ischemic brain damage. 5 Accordingly, immune modulation (immunotherapy) has become a promising concept for stroke treatment. [6] [7] [8] Recent studies have revealed that mobilization of CD4 + CD25 + regulatory T cells (Tregs), a specialized population of T cells, is an endogenous mechanism of immune modulation and attenuates poststroke inflammation by counterbalancing activation of immune effector cells. [9] [10] [11] [12] Depletion of Tregs profoundly augmented the activation of resident and invading inflammatory cells and increased ischemic brain damage. 10 Our previous studies have demonstrated that adoptive transfer of Tregs provided acute protection to the ischemic brain and mitigated cerebral inflammation. 11, 13 The early anti-inflammatory effect of adoptively transferred Tregs did not require passage across the blood-brain barrier (BBB). Rather, these cells inhibited matrix metallopeptidase 9 (MMP-9) production by peripheral neutrophils, thus preventing proteolytic damage to the BBB. 11 The immunosuppressive function of Tregs usually requires local cell proximity or even direct cell-cell interactions. [14] [15] [16] We have found that the crosstalk between Tregs and neutrophils was cell-cell contact dependent and that inhibitory signaling through programmed death ligand-1 (PD-L1) was essential for the protective effect of Tregs. 13 However, it is unclear where and how Tregs gain proximity to circulating neutrophils and inhibit neutrophil activation after stroke. The migration of immune cells toward sites of inflammation is activated through their expression of various chemokine receptors that recognize chemokines released by the inflamed or injured tissue. C-C chemokine receptor type 5 (CCR5) is a chemokine receptor that is highly expressed on T cells. It mediates T-cell trafficking out of secondary lymphoid organs toward sites of inflammation. [17] [18] [19] CCR5 + T cells have been shown to play important roles in atherosclerosis, 20 rheumatoid arthritis, 21 and autoimmune encephalomyelitis. 22 Interestingly, CCR5 is expressed preferentially on Tregs compared with other CD4 + T cells under certain pathological conditions and exerts multifaceted functions in addition to chemotaxis. 23 In particular, Treg CCR5 expression has been associated with their homing to the infarcted heart and their suppressive effects on local inflammation. 24 CCR5 knockout in Tregs results in an increased magnitude of adaptive immune reactivity in fungal and parasitic infection. 23, 25 The function of CCR5 in Treg responses toward cerebral ischemia is unknown.
In the current study we demonstrate that CCR5 activation is critical for the docking of adoptively transferred Tregs at the ischemia-injured endothelium where Tregs interact with blood-borne neutrophils/macrophages. Moreover, the engagement of Treg CCR5 with its ligand CCL5 upregulates the expression of PD-L1, enhancing the inhibitory effect of Tregs on neutrophil-derived MMP-9. Therefore, CCR5 is a critical molecule for Treg-mediated BBB protection and may represent a novel target to optimize Treg-based cell therapy for ischemic stroke.
Materials and Methods

Mice
All animal experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee and performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Male 8-to 12-week old C57BL/6J mice, and B6.129P2-Ccr5 tm1Kuz /J mice (C57/BL6 background) were purchased from The Jackson Laboratory (Bar Harbor, ME).
Cerebral Ischemia Model
Mice were anesthetized with 3% isoflurane in 67%:30% N 2 O/ O 2 (induction), until they were unresponsive to the tail pinch test and were then fitted with a nose cone providing 1.5% isoflurane for anesthesia maintenance. A monofilament was introduced into the common carotid artery, advanced to the origin of the middle cerebral artery, and left in position for 60 minutes until reperfusion. Cerebral blood flow was measured using laser Doppler flowmeter to confirm the vascular occlusion and reperfusion. The rectal temperature was controlled at 37.0AE0.5°C during surgery and middle cerebral artery occlusion (MCAO) via a temperature-regulated heating pad. Immediately after surgery, animals were randomly assigned to splenocyte or Tregs treatment groups. Investigators were blinded to treatment groups during cell transplantation or vehicle injection and during all outcome assessments. Sham-operated animals underwent the same anesthesia and surgical procedures except MCAO.
Two-Dimensional Laser Speckle Imaging Techniques
In selected experiments cerebral blood flow was monitored using the laser speckle imaging technique (PeriCam PSI
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• Strategies that enhance C-C chemokine receptor type 5 signaling may potentiate the therapeutic effect of adoptively transferred regulatory T cells in stroke victims.
System; Perimed, J€ arf€ alla, Sweden) before MCAO, during ischemia, and after reperfusion. Cerebral blood flow changes were expressed as percentage of pre-MCAO baseline. Animals that did not show a cerebral blood flow reduction of at least 75% were excluded (fewer than 10% of stroke animals) from further experimentation. 
Measurement of Infarct Volume
Brains were removed and sliced into 7 coronal sections, each 1 mm thick. Sections were immersed in prewarmed 2% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma, St. Louis, MO) in saline for 10 minutes and then fixed in 4% paraformaldehyde. Animals that developed massive hemorrhage were excluded from further evaluation (about 2% of stroke animals). Infarct volume was determined with National Institutes of Health ImageJ analysis by an observer blinded to experimental group assignment.
Assessments of Neurological Deficit
Neurological deficit was assessed in a blinded fashion using a 5-point neurological score in mice: 0, no observable deficit; 1, torso flexion to right; 2, spontaneous circling to right; 3, leaning/falling to right; 4, no spontaneous movement; 5, death.
Real-Time Polymerase Chain Reaction
Total RNA was isolated from ischemic brains 24 hours after stroke using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Five micrograms was used to synthesize the first strand of cDNA using the Superscript First-Strand Synthesis System for Real-Time Polymerase Chain Reaction (RT-PCR) (Invitrogen, Carlsbad, CA). PCR was performed on the Opticon 2 Real-Time PCR Detection System (Bio-Rad, Hercules, CA) using corresponding primers (Table S1 ) and SYBR green PCR Master Mix (Invitrogen). The cycle time values were normalized with glyceraldehyde 3-phosphate dehydrogenase of the same sample. The expression levels of mRNAs were then calculated and expressed as fold changes versus sham control.
Two-Photon In Vivo Imaging
For brain 2-photon imaging, a 5.0-mm craniotomy was performed 1.0 mm posterior and 2.5 mm lateral from the bregma. 26 The Figure S1 ) was injected. For simultaneous fluorescence excitation of Alexa-Fluora-488, Rhodamine-6G, and CellTracker ™ Deep Red Dye, a 790-nm wavelength was used.
Imaging data were captured using an Olympus multiphoton microscope (FLUOVIEW FV1000, System Version 3.1.1.9, Tokyo, Japan) equipped with a Spectra-Physics DeepSee Mai Tai Ti-Sapphire laser (Newport Inc, Mountain View, CA) and a 1.05 NA 259MPE water immersion objective lens. Images were acquired of the top 100 lm of the cortex including the pial vasculature with a resolution of 5089508 lm (102491024 pixels/image). The dwell time was set to 2 ls/pixel. After acquisition, images were processed and analyzed with Fuji and Imaris (Bitplane, Belfast, UK). Mean track velocities (lm/min) were calculated for individual tracks spanning 200 seconds. All track calculations were performed using a Fuji manual tracking plug-in.
Image Processing and Analysis
Cerebral T-cell, macrophage, and neutrophil infiltration was quantified in a blinded manner in both the cortex and striatum at 2 coronal levels (0.2 and À0.5 mm relative to bregma). All images were processed with Image J for cell-based counting of automatically recognized cells. The mean was calculated from 3 fields in the cortex or striatum of each section as mean number of cells per square millimeter. The length of CD31 and CCL5 immunopositive blood vessels was measured using ImageJ in both the cortex and striatum at the same coronal levels described above and adjusted to the total length per square millimeter. The 2-photon images were analyzed using Fuji plug-in. Briefly, image sequences were imported to Fuji, and the manual cell track was initiated. Cells of interest were clicked from the first time frame to the last one, and a cell track route image was constructed. Cell velocity was calculated in micrometers per minute. 28 The cell-cell contact time was determined by manually examining each Treg-endothelium or Treg-neutrophil/macrophage interaction; no contact was recorded if black pixels were visualized between the cells. 29 Cell displacement was calculated using Microsoft Excel as previously described.
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In Vitro BBB Permeability Assay
Mouse endothelial cells were grown to confluence in the transwell system and subjected to oxygen glucose deprivation (OGD) for 4 hours. Neutrophils and Tregs isolated from donor mice were treated with TNF-a (100 ng/mL) or CCR5 inhibitor DAPTA (D-ala-peptide T-amide; 100 ng/mL) at 37°C for 2 hours and washed with PBS before being added to the upper chamber (1:1, 10 5 /well). Fluorescence-labeled dextran (4.4 kDa Alexa-Fluorer 488 Dextran, Invitrogen) was added into the upper chamber. Culture medium in the lower chamber was collected and measured once an hour after reoxygenation until 6 hours after OGD. The amount of dextran leakage represented the BBB permeability.
Flow Cytometry
For in vivo study, single-cell suspensions were obtained from blood, spleen, and lymph nodes. Red blood cells were removed from blood and splenocyte suspensions using erythrocyte lysis buffer (Ammonium Chloride Potassium, Invitrogen). Cells were stained and analyzed by flow cytometry for CCR5 expression on CD4 + CD25 + Foxp3 + Tregs. For in vitro study, cells were collected from a neutrophil-Treg-endothelial cell coculture system. MMP-9 and PD-L1 were stained and analyzed in neutrophils (Gr-1 + ) and Tregs (CD25 + ), respectively.
Statistical Analysis
Results are presented as meanAESEM. The difference in means between 2 groups was assessed by 2-tailed Student t test. Differences in means among multiple groups were analyzed using 1-or 2-way ANOVA with time or treatment as independent factors. When ANOVA showed significant differences, pairwise comparisons between means were tested by post hoc Bonferroni tests. In all analyses, P≤0.05 was considered statistically significant.
Results
CCR5 Expression Is Essential for a Neuroprotective Effect of Tregs Against Transient Cerebral Ischemia
Recent studies have reported the protective effect of adoptively transferred Tregs after cerebral ischemia.
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However, it remains unclear where and how these transferred Tregs exert their protection. CCR5, a chemokine receptor that guides T-cell trafficking, has been shown to preferentially express on Tregs compared with other CD4 + T cells under certain pathological conditions. 23 We therefore examined the Figure 1F ). These data indicate that CCR5 is indispensable for Treg-afforded neuroprotection against cerebral ischemic injury.
CCR5 Maintains the Transferred Tregs at the Injured Endothelium in the Ischemic Brain
We then explored the mechanism by which CCR5 contributed to the protective effect of Tregs against ischemic stroke. Because CCR5 is known to be important for immune cell recruiting, we first examined whether CCR5 guides the recruitment of the transferred Tregs to the injured barrier. Two-photon in vivo imaging was performed to observe transferred Tregs in the ischemic area after MCAO. Circulating myeloid cells (mainly neutrophils and macrophages) of the recipient stroke mice were labeled by intravenous injection of rhodamine 6G (red cells in Figures 2 and 3 ). Dextran-Alexa Fluoro-488 (70 kDa) was infused intravenously to visualize the blood vessels. Tregs isolated from CCR5 knockout mice or WT mice were labeled with cell tracker (pseudocolored in blue in Figures 2 and 3 ) and transferred intravenously after the baseline image was acquired. Time-lapse imaging was conducted at the ischemic region through a cranial window À/À donor mice. Control mice received the same number of splenocytes (Sp). Animals were euthanized at 3 days after stroke. A, Representative laser speckle imaging of cerebral blood flow (CBF) before (baseline), during (ischemia), and after MCAO (reperfusion). B, Quantification of CBF as percentages of the preischemia levels. C, Representative images of 2,3,5-triphenyltetrazolium chloride (TTC) staining for infarct measurement. D, Quantification of infarct volume. E, Quantification of brain edema. F, Neurological score evaluated during the first 3 days after stroke. n=5/group. *P≤0.05, **P≤0.01, ***P≤0.001. CCR5 indicates C-C chemokine receptor type 5; Treg, regulatory T cell.
( Figure 2C ). However, the migration speed of WT Tregs was significantly lower compared with the CCR5 À/À Tregs ( Figure 2D ). Consistently, the contact time of infiltrated Tregs with the endothelium was significantly elongated by CCR5 expression on the Tregs ( Figure 2E through 2H) . Meanwhile, the contact time between infused Tregs and endogenous neutrophil/macrophages was significantly longer for WT Tregs than CCR5 À/À Tregs ( Figure 2I through 2L ). These data suggest that although CCR5 expression on Tregs may not increase the recruitment of Tregs to the lesion site significantly, it is important to maintain Tregs at the lesion site and meanwhile increase the interaction among Tregs, endothelium, and neutrophils/macrophages. Interestingly, the migration speed of neutrophils/macrophages was significantly faster in WT Treg-infused mice compared with splenocyte or CCR5 À/À Treg-infused mice ( Figure 3A through 3C ).
CCR5 Ligands are Upregulated in the Injured Endothelium of the Ischemic Brain
To further confirm a Treg-endothelium interaction involving CCR5, we then examined the expression of CCR5 ligands, including CCL3, CCL4, and CCL5 in the ischemic brain. As shown in Figure 4A , mRNA expression of CCL3 and CCL5, but not CCL4, increased significantly in the brain 1 day after MCAO. Immunofluorescence staining confirmed an elevation of CCL5 protein expression in CD31 + endothelial cells in the ischemic penumbra 1 day post-MCAO ( Figure 4B ). The length of CCL5 + CD31 + colocalization along blood vessels increased significantly 1 day after stroke as compared with sham mice ( Figure 4C ). Consistent with the in vivo data, in vitro cultured endothelial cells exhibited increased expression of CCL5 after 4 hours of OGD ( Figure 4D and 4E) . The expression of CCL3, another ligand of CCR5, was also elevated in the ischemic brain. However, the Iba-1 + microglia (Figure 4F and 4H; Figure S2 ) but not CD31 + endothelial cells ( Figure 4F and 4G) are the main cellular source of CCL3 in the ischemic brain. Consistent with the increase in CCL5 expression in endothelium, expression of CCR5 on endogenous Tregs increased after cerebral ischemia. We collected peripheral blood, spleen, and lymph nodes from sham or stroke mice at (Figure 5C and 5D). The mean fluorescence intensity of CCR5 on blood Tregs and spleen Tregs also significantly increased after stroke ( Figure 5E ). Cerebral ischemia showed no effect on CCR5 expression on Tregs isolated from lymph nodes ( Figure 5C through 5E). Immunostaining further confirmed the expression of CCR5 on Tregs isolated from blood of WT mice at 1 day after MCAO but not on Tregs from CCR5 À/À mice ( Figure 5F ).
Taken together, these data suggest that the expression of CCL5 significantly increased on injured endothelium, which could lead to the interaction between endothelium and CCR5-expressed circulating Tregs. The data also revealed a reduction of circulating Tregs after stroke, which suggest a potential need for Treg supplementation.
CCR5 Expression by Transferred Tregs Plays an Important Role in Their Protective Effect Against BBB Disruption Early After Stroke
With the CCR5-mediated docking of transferred Tregs on the injured endothelium, Tregs gain proximity to the ischemic barrier. We next tested whether CCR5 was essential for transferred Treg-afforded protection against BBB disruption after cerebral ischemia. 11 We found that loss of CCR5 expression on Treg reversed their protective effect against BBB damage with significantly increased IgG leakage in CCR5 À/À Treg-treated stroke mice as compared to that in the WT Treg-treated mice (Figure 6A through 6C) . Consistently, infiltration of Gr1 + neutrophils ( Figure 6D and 6E We further confirmed the role of CCR5 on Treg-mediated protection against BBB damage using an in vitro endothelial cell-based model of BBB ( Figure 7A ). In vitro BBB models have been used for decades to explore the cellular and molecular mechanisms underlying BBB damage or protection. 34 BBB integrity changes can be addressed by measuring cell monolayer permeability to different sized tracers. Here, leakage of 4.4-kDa dextran was measured up to 6 hours of reperfusion after OGD. As shown in Figure 7B , the integrity of the BBB was disrupted progressively from 1 to 6 hours after reperfusion. The addition of TNF-a-pretreated neutrophils significantly enhanced BBB damage after OGD. Although Tregs showed minimal effect on BBB damage in the absence of neutrophils (not shown), adding Tregs into the endothelial cell-neutrophil coculture system significantly reduced dextran leakage, suggesting an inhibitory effect of Treg on neutrophilenhanced BBB damage ( Figure 7C ). Interestingly, pretreatment with DAPTA, a CCR5 inhibitor, reduced Treg-mediated protection against the BBB leakage in the endothelial cellneutrophil coculture system ( Figure 7C ). Similarly, genetic knockout of CCR5 on Tregs significantly removed their protective effect on the BBB ( Figure 7C ). Collectively, these findings reveal that CCR5 plays an important role in Tregs' protection against neutrophilenhanced BBB leakage after ischemic challenge.
CCR5 Activation Enhances the Immune Inhibitory Function of Tregs on Neutrophils
It is reported that CCR5 engagement on Tregs may promote other biological functions beyond cell recruiting or docking. 35 Therefore, we used CCL5, the chemokine expressed by ischemic brain endothelial cells ( Figure 4B and 4C) , to activate the CCR5 receptor on enriched Tregs in vitro. Realtime polymerase chain reaction showed that CCL5 at a concentration of 0.04 lmol/L primed Tregs to express higher mRNA levels of the coinhibitory cell surface molecule PD-L1 and the immunosuppressive cytokine interleukin-10 (IL-10) ( Figure 8A ). After CCL5 stimulation there was a trend toward increased mRNA expression of CD39, CTLA-4, and transcription factor FOXp3 ( Figure 8A) . PD-L1 has been shown to be a critical molecule that mediates Tregs' inhibition of neutrophils. 11 We therefore further assessed the influence of CCR5 on the expression and function of PD-L1 in a Treg-neutrophil-endothelial coculture system. Tregs were cocultured with OGD-challenged endothelial cells and TNF-a-activated neutrophils for 24 hours. Flow cytometry was used to identify CD25 + Tregs and Gr1 + neutrophils ( Figure 8B ). As shown in Figure 8C and 8D, the mean fluorescence intensity of PD-L1 on Tregs increased significantly after being cocultured with OGD-challenged endothelial cells and neutrophils as compared with the naive Tregs. Blocking CCR5 on Tregs (by pretreating Tregs with DAPTA at a concentration of 100 ng/mL) significantly attenuated the increase in PD-L1 expression ( Figure 8C and  8D) , suggesting the critical role of CCR5 in PD-L1 expression on Tregs. Meanwhile, we measured neutrophil MMP-9 expression by flow cytometry in the coculture system. Blocking CCR5 on Tregs with DAPTA significantly impaired the inhibitory effect of Tregs on neutrophil-derived MMP-9 in the coculture system ( Figure 8E and 8F) . We then tested the influence of CCL5 priming of Tregs on inhibition of MMP-9 production from neutrophils in a neutrophil-Treg coculture system. MMP-9 production by neutrophils cocultured with CCL5-primed Tregs was lower than that from those cocultured with the unprimed Tregs ( Figure 8G ). Finally, we confirmed in vivo that WT Tregs significantly inhibited MMP-9 elevation in the plasma after ischemic stroke, whereas CCR5 À/À Tregs failed to do so ( Figure 8H ). Furthermore, adoptive transfer of WT Tregs, but not CCR5 À/À Tregs, significantly reduced MMP-9 expression in infiltrated neutrophils ( Figure 8I ). Collectively, these data suggest that CCL5-primed Tregs exhibit stronger immune inhibitory function against neutrophils. Taken together, our data suggest that CCR5 signaling mediates the upregulation of PD-L1 on Tregs once recruited to the ischemic BBB, which subsequently inhibits MMP-9 production by neutrophils through enhanced (Treg)/PD-1 (neutrophil) signaling. 12 
Discussion
Previous preclinical studies have revealed a potent protective effect of Tregs in ischemic stroke. 9, 11 Moreover, several recent clinical trials using adoptive Treg therapy in human inflammatory diseases have reported promising results, [36] [37] [38] [39] [40] [41] arousing interest in Treg therapy of stroke. The current study elucidates the importance of CCR5 for the protective effect of adoptively transferred Tregs in ischemic stroke. The results reveal that CCR5 is important for the accumulation of Tregs at the ischemic BBB. Moreover, CCR5 signaling enhances the inhibitory effect of transferred Tregs on neutrophil-derived MMP-9 ( Figure 9 ). These 2 mechanisms endorse CCR5 as a critical molecule for Treg-afforded BBB protection early after ischemic stroke. This discovery may provide new strategies to enhance the therapeutic effect of Tregs in ischemic stroke. CCR5 is well known to be responsible for the chemotaxis of immune cells. It is responsive to different chemokines, including CCL3, CCL4, and CCL5. Our data showed that the expression of CCR5 on endogenous Tregs increased significantly after ischemia, which was accompanied by elevated CCL5 expression on endothelial cells and increased CCL3 expression on microglia. These data suggest a potential role of CCR5 in Treg function in the ischemic brain. Considering that adoptively transferred Tregs do not enter the brain parenchyma until 3 to 5 days after stroke, 10,11 CCL5 + endothelial cells might play more important roles than CCL3 + microglia in the initial recruitment and/or docking of Tregs in early response after ischemia. Actually, CCR5-CCL5 interaction has been reported previously to be important for Treg recruitment to tumors. 42, 43 Interestingly, our studies using 2-photon in vivo imaging revealed that the loss of CCR5 expression resulted in a slight, but not significant, decrease in the number of Tregs in the observed area. This Treg CCR5 deficiency resulted in prominently increased traveling velocity of the Tregs. This result indicates that CCR5 expression on Figure 7 . CCR5 is indispensable for Treg-mediated protection against oxygen-glucose deprivation (OGD)-induced blood-brain barrier (BBB) damage. A, Illustration of in vitro experimental design. A mouse endothelial cell monolayer was seeded on top of a membrane in the cell culture insert and subjected to OGD for 4 hours. After reoxygenation, isolated neutrophils with TNF-a pretreatment (100 ng/mL) and preactivated Tregs were added into the insert. Then, 4.4-kDa Dextran-Alexa-488 was loaded in the abluminal side. Paracellular permeability was determined by measuring the fluorescence intensity of the culture media in the lower chamber. n=6/group, data are from 2 repeats of independent experiments. B, Dextran-Alexa-488 leakage was measured 1 to 6 hours after OGD in different groups. C, BBB integrity was measured by quantifying fluorescence intensity in the culture medium in the lower chamber 6 hours after OGD. Pharmacological inhibition (with DAPTA 100 ng/mL) or genetic depletion of CCR5 abolished Tregmediated protection of BBB integrity after OGD. *P≤0.05, **P≤0.01, ***P≤0.001. CCR5 indicates C-C chemokine receptor type 5; DAPTA, D-ala-peptide T-amide; Treg, regulatory T cell.
Tregs can slow down the adoptively transferred Tregs at the site of BBB injury, allowing more time for interaction between Tregs and the injured BBB. In support of this notion, loss of CCR5 expression reduced the contact time between Tregs and endothelial cells.
In contrast to the increased migration speed of CCR5
Tregs, the speed of neutrophils/macrophages in the infarct area of CCR5 À/À Treg-treated animals was much slower than that in the WT Treg-treated animals. Mounting evidence has suggested the critical role of neutrophils and macrophages in BBB disruption after cerebral ischemic stroke. [44] [45] [46] [47] After cerebral ischemia, the neutrophil flow in the blood vessels slows down prominently, and this is accompanied by the progressive adherence of neutrophils to the inflamed vasculature of the ischemic brain. 47, 48 Therefore, the reduced speed of neutrophil/macrophage movement that we observed in CCR5 À/À Treg-or PBS-treated stroke mice may allow the infiltration of these peripheral proinflammatory cells. This result is consistent with the immunostaining data showing increased infiltration of neutrophils and macrophages into the ischemic brain 1 day (Figure 6 ) after stroke. WT Treg treatment, but not the CCR5 À/À Treg treatment, reduced the influx of neutrophils after stroke. Taken together, Treg CCR5 expression increases Tregs' contact with injured endothelium and enhances interaction with other immune cells, preventing these immune cells from lingering in the ischemic area. In addition to the docking of Tregs, the current study shows that CCR5 signaling plays an important role in promoting Tregs' postischemia immunosuppressive function. Tregs primed with CCL5 expressed higher levels of PD-L1, a suppressive coregulatory protein. We previously have identified PD-L1 as an essential signaling molecule between Tregs and neutrophils in BBB protection following ischemic stroke.
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CCR5 signaling in Tregs may further upregulate the expression of PD-L1 and subsequently enhance the inhibitory effect of Tregs on MMP-9 production by neutrophils. In addition to PD-L1, CCR5 expression also influences the expression of CTLA-4 and CD39, both of which are shown to be critical for the immunosuppressive functions of Tregs. 49, 50 It is noted that CCR5 activation also significantly increased IL-10 expression by Tregs. IL-10 has been shown to be important for endogenous Treg-afforded protection of the ischemic brain. 10 However, our previous study suggested that although adoptive Treg transfer elevated the number of IL-10-producing Tregs in the blood and spleen of stroke mice, IL-10 was not critical for Treg-afforded BBB protection. 11 Whether CCL5-induced upregulation of IL-10 is important for other beneficial effects of Tregs warrants further exploration. Endothelial cells are also important sources of MMP-9 in response to ischemic challenge. 51, 52 However, Tregs do not show inhibition on MMP-9 production in endothelia-Treg coculture without neutrophils (data not shown). It is noted that CCR5 is not specifically expressed on Tregs but is also expressed on other types of T cells including the recently characterized CCR5 + CD4 + Foxp3 + CD25 À T cells. CCR5-mediated Treg docking and activation at the ischemic blood-brain barrier. In response to cerebral ischemic stroke, the endothelial cells express CCL5, which mediates the adoptively transferred Tregs to dock at the ischemic blood-brain barrier.
Once engaged with CCL5, CCR5 is activated and upregulates the expression of PD-L1 on Tregs, which inhibits the production of MMP-9 from neutrophils. As a result, CCR5 signaling contributes to Treg-afforded protection of the blood-brain barrier after ischemic stroke. CCL5 indicates ligand for CCR5; CCR5, C-C chemokine receptor type 5; Treg, regulatory T cell.
These CCR5 + CD4 + Foxp3 + CD25 À cells are not regulatory cells, and adoptive transfer of these cells exacerbates atherosclerosis. 20 In our study we focused on the importance of CCR5 in adoptively transferred Tregs and the underlying mechanism of protection. Based on our results, CCR5 expression specifically on adoptively transferred Tregs is essential for their therapeutic effects. How CCR5 influences the brain targeting and function of endogenous Tregs is another important question that warrants further study in the future. However, because CCR5 is widely expressed in almost all types of CD4 + T cells, it is challenging to specifically target CCR5 expression on endogenous Tregs for their therapeutic purpose. In summary, this study demonstrates that CCR5 signaling is indispensable for the ability of adoptively transferred Tregs to protect the ischemic BBB. Activation of CCR5 enhances interactions between Tregs and endothelial cells and increases the immune suppressive function of Tregs by upregulating PD-L1 expression. In light of the importance of CCR5 in Treg function, strategies that enhance CCR5 signaling may potentiate the therapeutic effect of adoptively transferred Tregs. Future studies are warranted to evaluate the application of these approaches to optimize Treg treatment after stroke.
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